Overview

Metformin for the Prevention of CRA Recurrence

Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
Most of the sporadic colorectal cancer (CRC )develop from colorectal adenoma (CRA), patients with CRA have a high risk of recurrence and development of metachronous CRA or CRC after removal, therefore, the investigators conducted this clinical trial to explore the chemoprevetion effect of metformin for CRA recurrence after removal.
Phase:
N/A
Details
Lead Sponsor:
Jing-yuan Fang, MD, Ph. D
Treatments:
Metformin